Anti-Obesity Effect of Lactobacillus gasseri BNR17 in
High-Sucrose Diet-Induced Obese Mice
Ji-Hee Kang*, Sung-Il Yun, Mi-Hee Park, Jun-Hong Park, So-Young Jeong, Han-Oh Park
R&D center, Bioneer Corporation, Daejeon, Republic of Korea
Previously, we reported that Lactobacillus gasseri BNR17 (BNR17), a probiotic strain isolated from human breast milk,
inhibited increases in body weight and adipocyte tissue weight in high-sucrose diet-fed Sprague-Dawley (SD) rats and
reduced glucose levels in type 2 diabetes mice. In the current study, we conducted further experiments to extend these
observations and elucidate the mechanism involved. C57BL/6J mice received a normal diet, high-sucrose diet or high-
sucrose diet containing L. gasseri BNR17 (109or 1010CFU) for 10 weeks. The administration of L. gasseri BNR17 significantly
reduced the body weight and white adipose tissue weight regardless of the dose administered. In BNR17-fed groups, mRNA
levels of fatty acid oxidation-related genes (ACO, CPT1, PPARa, PPARd) were significantly higher and those of fatty acid
synthesis-related genes (SREBP-1c, ACC) were lower compared to the high-sucrose-diet group. The expression of GLUT4,
main glucose transporter-4, was elevated in BNR17-fed groups. L. gasseri BNR17 also reduced the levels of leptin and insulin
in serum. These results suggest that the anti-obesity actions of L. gasseri BNR17 can be attributed to elevated expression of
fatty acid oxidation-related genes and reduced levels of leptin. Additionally, data suggested the anti-diabetes activity of L.
gasseri BNR17 may be to due elevated GLUT4 and reduced insulin levels.
Citation: Kang J-H, Yun S-I, Park M-H, Park J-H, Jeong S-Y, et al. (2013) Anti-Obesity Effect of Lactobacillus gasseri BNR17 in High-Sucrose Diet-Induced Obese
Mice. PLoS ONE 8(1): e54617. doi:10.1371/journal.pone.0054617
Editor: Kathrin Maedler, University of Bremen, Germany
Received July 8, 2012; Accepted December 13, 2012; Published January 30, 2013
Copyright: ? 2013 Kang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by High Value-Added Food Technology Development Program; Ministry for Food, Agriculture, Forestry and Fisheries,
Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: All authors are employed by the Bioneer Corporation. Bioneer Co. has patents for Lactobacillus gasseri BNR17. This does not alter the
authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: email@example.com
Obesity is caused by a multiple factors, including genetic,
metabolic, behavioral and cultural factors. More specifically, a high
fat intake and low energy expenditure are the main causes of
obesity, as well as metabolic disorders such as insulin resistance,
type 2 diabetes, and cardiovascular diseases [1,2]. A variety of
programs and treatments including drug therapeutics, surgical
intervention and dietary control for obesity management or
prevention have been developed; however, these are often
associated with safety issues. Therefore, the development of a safe
and effective dietary supplement to assist with body weight
management is essential.
Lactobacilli and bifidobacteria are representative probiotic
microorganisms that benefit human health through modulation
of the immune system , prevention of cancer , enhancement
of intestinal functions  and a hypocholesterolemic effect .
Recently, some studies have expended the functionality of
probiotics to obesity management. Some probiotics have been
demonstrated to have an anti-obesity property by regulating lipid
and glucose metabolism [7,8], producing conjugated linoleic acid
[9,10], reducing the adipocyte size and increasing the number of
small adipocytes in white adipose tissue , and regulating leptin
We have observed the effects of L. gasseri BNR17, a probiotic
strain isolated from human breast milk, on the high-sucrose diet-
fed SD rat and transgenic db/db mouse [13,14]. In those studies, L.
gasseri BNR17 suppressed the body weight and fat weight gain,
fasting and postprandial blood glucose, and improved oral glucose
tolerance. The purpose of the current study was to extend these
observations and elucidate the mechanism involved in the anti-
obesity activity of L. gasseri BNR17. We investigated the impact of
L. gasseri BNR17 on body weight gain, fat accumulation, and
mRNA expression of obesity-related genes in diet-induced obese
Materials and Methods
Animals and Experiment
Male C57BL/6J mice (6-week-old, n=8 per group) were
obtained from Central Lab Animal Inc. (Seoul, South Korea).
All animals were housed in standard plastic cages (two mice per
cage), and maintained under a 12-h light-dark cycle at constant
temperature and humidity (2361uC and 5565%, respectively)
with free access to food and water. This study was carried out in
accordance with the recommendations in the guide for the care
and use of the Animal, Plant and Fisheries Quarantine and
Inspection Agency (Republic of Korea). The protocol was
approved by the Committee on the Ethics of Animal Experiments
of the Bioneer Corporation (AEC-20081229-0004). Following
acclimatization for 1 week, the mice were fed a normal diet (ND)
(2918C, containing 6.0% fat and 18.5% protein by weight;
Koatech Animal Inc., Pyeongtaek, South Korea), or a high-
sucrose diet (HSD) (AIN-76A, 5.0% fat, 50.0% sucrose, 15.0%
cornstarch and 20.0% protein by weight; Central Lab Animal
Inc.), or high-sucrose diet and BNR17 109CFU (HSD+BNR17(9))
PLOS ONE | www.plosone.org1January 2013 | Volume 8 | Issue 1 | e54617
31. Park DY, Ahn YT, Huh CS, Jeon SM, Choi MS (2011) The inhibitory effect of
Lactobacillus plantarum KY1032 cell extract on the adipogenesis of 3T3-L1 cells.
J Med Food 14: 670–675.
32. Furuhashi M, Hotamisligil GS (2008) Fatty acid-binding proteins: Role in
metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7: 489–
33. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, et al. (1998) Nutritional and
insulin regulation of fatty acid synthetase and leptin gene expression through
ADD1/SREBP1. J Clin Invest 101: 1–9.
34. Guillou H, Martin PG, Pineau T (2008) Transcriptional regulation of hepatic
fatty acid metabolism. SubCell Biochem 49: 3–47.
35. Evrard B, Coudeyras S, Dosgilbert A, Charbonnel N, Alame ´ J, et al. (2011)
Dose-dependent immunomodulation of human dendritic cells by the probiotic
Lactobacillus rhamnosus Lcr35. PLos one 6: e18735.
36. Zorzano A, Palacı ´n M, Guma ` A (2005) Mechanisms regulating GLUT4 glucose
transporter exrpression and glucose transport in skeletal muscle. Acta Physiol
Scand 183: 43–58.
37. Kouidhi S, Berrhouma R, Rouissi K, Jarboui S, Clerget-Froidevaux MS, et al.
(2011) Human subcutaneous adipose tissue Glut4 mRNA expression in obesity
and type 2 diabetes. Acta Diabetol (in press).
38. Taba ´k AG, Herder C, Rathmann W, Brunner EJ, Kivima ¨ki M (2012)
Prediabetes: A high-risk state for diabetes development. Lancet 379: 2279–2290.
39. Ma X, Hua J, Li Z (2008) Probiotics improve high fat diet-induced hepatic
steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 49:
40. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, et al. (2007) Selective
increases of bifidobacteria in gut microflora improve high-fat-diet-induced
diabetes in mice through a mechanism associated with endotoxaemia. Diabetol
41. Blaut M, Bischoff SC (2010) Probiotics and obesity. Ann Nutr Metab 57 (Suppl.
Anti-Obesity Effect of Lb. gasseri BNR17
PLOS ONE | www.plosone.org8 January 2013 | Volume 8 | Issue 1 | e54617